Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy

References

• ParkinDMBrayFFerlayJPisaniPGlobal cancer statistics, 2002CA Cancer J Clin2005557410815761078
   PubMed Web of Science ®Google Scholar
• BurrisHA3rdMooreMJAndersenJImprovements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trialJ Clin Oncol199715240324139196156
   PubMed Web of Science ®Google Scholar
• MooreMJGoldsteinDHammJErlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials GroupJ Clin Oncol2007251960196617452677
   PubMed Web of Science ®Google Scholar
• GrantSFisherPBDentPThe role of signal transduction pathways in drug and radiation resistanceCancer Treat Res20021128910812481713
   PubMedGoogle Scholar
• SmitVTBootAJSmitsAMFleurenGJCornelisseCJBosJLKRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomasNucleic Acids Res198816777377823047672
   PubMed Web of Science ®Google Scholar
• AlmogueraCShibataDForresterKMartinJArnheimNPeruchoMMost human carcinomas of the exocrine pancreas contain mutant c-K-ras genesCell1988535495542453289
   PubMed Web of Science ®Google Scholar
• DeramaudtTRustgiAKMutant KRAS in the initiation of pancreatic cancerBiochim Biophys Acta200517569710116169155
   PubMed Web of Science ®Google Scholar
• FjallskogMLLejonklouMHObergKEErikssonBKJansonETExpression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumorsClin Cancer Res200391469147312684421
   PubMed Web of Science ®Google Scholar
• TobitaKKijimaHDowakiSEpidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasisInt J Mol Med20031130530912579331
   PubMed Web of Science ®Google Scholar
• UedaSOgataSTsudaHThe correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinomaPancreas200429e1e815211117
   PubMed Web of Science ®Google Scholar
• BloomstonMBhardwajAEllisonECFrankelWLEpidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray techniqueDig Surg200623747916717472
   PubMed Web of Science ®Google Scholar
• MorganMAParselsLAKollarLENormolleDPMaybaumJLawrenceTSThe combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancerClin Cancer Res2008145142514918698032
   PubMed Web of Science ®Google Scholar
• BrunsCJSolorzanoCCHarbisonMTBlockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinomaCancer Res2000602926293510850439
   PubMed Web of Science ®Google Scholar
• NgSSTsaoMSNickleeTHedleyDWEffects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinomaMol Cancer Ther2002177778312492110
   PubMed Web of Science ®Google Scholar
• FriessHBerberatPSchillingMKunzJKorcMBuchlerMWPancreatic cancer: the potential clinical relevance of alterations in growth factors and their receptorsJ Mol Med19967435428834768
   PubMed Web of Science ®Google Scholar
• FengJAdsayNVKrugerMExpression of ERRP in normal and neoplastic pancreata and its relationship to clinicopathologic parameters in pancreatic adenocarcinomaPancreas20022534234912409827
   PubMed Web of Science ®Google Scholar
• CiardielloFTortoraGEGFR antagonists in cancer treatmentN Engl J Med20083581160117418337605
   PubMed Web of Science ®Google Scholar
• LiJZhaoMHePHidalgoMBakerSDDifferential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymesClin Cancer Res2007133731373717575239
   PubMed Web of Science ®Google Scholar
• LynchTJBellDWSordellaRActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibN Engl J Med20043502129213915118073
   PubMed Web of Science ®Google Scholar
• ChungCHMirakhurBChanECetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactoseN Engl J Med20083581109111718337601
   PubMed Web of Science ®Google Scholar
• BaselgaJPfisterDCooperMRPhase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatinJ Clin Oncol20001890491410673534
   PubMed Web of Science ®Google Scholar
• OhDLeeKLeeKA phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancerJ Clin Oncol200826May 20 Suppl Abstract 4638
   Google Scholar
• MiksadRASchnipperLGoldsteinMDoes a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value?J Clin Oncol20072545064507 author reply 817906218
   PubMed Web of Science ®Google Scholar
• FountzilasGBobosMKalogera-FountzilaAGemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluationCancer Invest20082678479318798073
   PubMed Web of Science ®Google Scholar
• XiongHQRosenbergALoBuglioACetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II TrialJ Clin Oncol2004222610231615226328
   PubMed Web of Science ®Google Scholar
• PhilipPABenedettiJFenoglio-PresierCPhase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 studyJ Clin Oncol200725LBA4509
   Web of Science ®Google Scholar
• BleickardtEArgirisARichRPhase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancerCancer Biol Ther2002164665112642688
   PubMed Web of Science ®Google Scholar
• BurtnessBThomasLSipplesRPhase II trial of weekly docetaxel/irinotecan combination in advanced pancreatic cancerCancer J20071325726217762761
   PubMed Web of Science ®Google Scholar
• BurtnessBAPowellMEBerlinDPhase II ECOG trial of irinotecan/docetaxel with or without cetuximab in metastatic pancreatic cancer: Updated survival and CA19–9 resultsJ Clin Oncol200826May 20 Suppl Abstract 4642
   Google Scholar
• Van CutsemEVervenneWLBennounaJPhase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancerJ Clin Oncol2009272231223719307500
   PubMed Web of Science ®Google Scholar
• KindlerHLGangadharTKarrisonTFinal analysis of a randomized phase II study of bevacizumab and gemcitabine plus cetuximab or erlotinib in patients with advanced pancreatic cancerJ Clin Oncol200826May 20 Suppl Abstract 4502
   Google Scholar
• KoAHDickeKGurtlerJPhase II, randomized, open-label study of cetuximab and bevacizumab alone or in combination with fixed-dose rate gemcitabine as first-line therapy for patient with metastatic adenocarcinoma of the pancreasGastrointestinal Cancers Symposium2009 January 15–17San Francisco, CA2009 Abstract 183
   Google Scholar
• DemolsAMahinCMarechalRCetuximab plus chemoradiation combined therapy for locally advanced inoperable pancreatic adenocarcinoma: A phase I studyJ Clin Oncol200826May 20 Suppl Abstract 4629
   Google Scholar
• MunterMTimkeCAdbollahiAFinal results of a phase II trial [PARC-Study ISRCTN56652283] for patients with primary inoperable locally advanced pancreatic cancer combining intensity modulated radiotherapy (IMRT) with cetuximab and gemcitabineJ Clin Oncol200826May 20 Suppl Abstract 4613
   Google Scholar
• LoehrerPJPowellMECardenesHRA randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201J Clin Oncol200826May 20 Suppl Abstract 4506
   Google Scholar
• Van CutsemEVervenneWLBennounaJHumbletYCosaertJRash as a marker for the efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: Results from the AViTA studyGastrointestinal Cancer Symposium2009 January 15–17San Franciso, CA2009 Abstract 117
   Google Scholar
• LiJKarlssonMOBrahmerJCYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitorsJ Natl Cancer Inst2006981714172317148773
   PubMed Web of Science ®Google Scholar
• RudinCMLiuWDesaiAPharmacogenomic and pharmacokinetic determinants of erlotinib toxicityJ Clin Oncol2008261119112718309947
   PubMed Web of Science ®Google Scholar
• LiJCusatisGBrahmerJAssociation of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patientsCancer Biol Ther2007643243817312388
   PubMed Web of Science ®Google Scholar
• FracassoPMBurrisH3rdArquetteMAA phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosingClin Cancer Res20071398699317289894
   PubMed Web of Science ®Google Scholar
• TejparSPeetersMHumbletYDose-escalation study using up to twice the standard dose of cetuximab in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST study): Preliminary dataJ Clin Oncol2006243554
   Google Scholar
• GebhardtFZankerKSBrandtBModulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1J Biol Chem1999274131761318010224073
   PubMed Web of Science ®Google Scholar
• HuangCLYangCHYehKHEGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatmentLung Cancer20096434635118995924
   PubMed Web of Science ®Google Scholar
• SequistLVMartinsRGSpigelDFirst-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutationsJ Clin Oncol2008262442244918458038
   PubMed Web of Science ®Google Scholar
• ImmervollHHoemDKugarajhKSteineSJMolvenAMolecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adeno-carcinomas: lack of mutations in the BRAF and EGFR genesVirchows Arch200644878879616598499
   PubMed Web of Science ®Google Scholar
• IyerRVRossiMBharthuarMEvaluation of phosphatidyl inositol 3-kinase catalytic subunit (PI3KCA) and epidermal growth factor receptor (EGFR) gene mutations in pancreatic adenocarcinomaGastrointestinal Cancers SymposiumJanuary 2009San Francisco, CA2009 Abstract 173
   Google Scholar
• KwakELJankowskiJThayerSPEpidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomasClin Cancer Res2006124283428716857803
   PubMed Web of Science ®Google Scholar
• MorinagaSSuganoNWadaHEpidermal growth factor receptor (EGFR) status: Mutation and protein expression, and clinicopathology of pancreatic ductal adenocarcinomaGastrointestinal Cancers Symposium2008 January 25–27Orlando, FL2008 Abstract 185
   Google Scholar
• CampERSummyJBauerTWLiuWGallickGEEllisLMMolecular mechanisms of resistance to therapies targeting the epidermal growth factor receptorClin Cancer Res20051139740515671571
   PubMed Web of Science ®Google Scholar
• DempkeWCHeinemannVResistance to EGF-R (erbB-1) and VEGF-R modulating agentsEur J Cancer2009In press
   Web of Science ®Google Scholar
• RexerBNEngelmanJAArteagaCLOvercoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonistsCell Cycle20098182219106609
   PubMed Web of Science ®Google Scholar
• BokemeyerCBondarenkoIHartmannJTKRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experienceJ Clin Oncol200826May 20 Suppl Abstract 4000
   Google Scholar
• JackmanDMSequistLVCioffrediLImpact of EGFR and KRAS genotype on outcomes in a clinical trial registry of NSCLC patients initially treated with erlotinib or gefitinibJ Clin Oncol200826May 20 Suppl Abstract 8035
   Google Scholar
• Van CutsemELangID’haensGKRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experienceJ Clin Oncol200826May 20 Suppl Abstract 2
   Google Scholar
• GuixMFaberACWangSEAcquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteinsJ Clin Invest20081182609261918568074
   PubMed Web of Science ®Google Scholar
• FrankeTFHornikCPSegevLShostakGASugimotoCPI3K/Akt and apoptosis: size mattersOncogene2003228983899814663477
   PubMed Web of Science ®Google Scholar
• MarmorMDSkariaKBYardenYSignal transduction and oncogenesis by ErbB/HER receptorsInt J Radiat Oncol Biol Phys20045890391314967450
   PubMed Web of Science ®Google Scholar
• JhawerMGoelSWilsonAJPIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximabCancer Res2008681953196118339877
   PubMed Web of Science ®Google Scholar
• BiancoRShinIRitterCALoss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitorsOncogene2003222812282212743604
   PubMed Web of Science ®Google Scholar
• EngelmanJAZejnullahuKMitsudomiTMET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signalingScience20073161039104317463250
   PubMed Web of Science ®Google Scholar
• IhleNTPaine-MurrietaGBerggrenMIThe phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenograftsMol Cancer Ther200541349135716170026
   PubMed Web of Science ®Google Scholar
• AbrahamRTGibbonsJJThe mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapyClin Cancer Res2007133109311417545512
   PubMed Web of Science ®Google Scholar
• BjornstiMAHoughtonPJThe TOR pathway: a target for cancer therapyNat Rev Cancer2004433534815122205
   PubMed Web of Science ®Google Scholar
• BiancoRGarofaloSRosaRInhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugsBr J Cancer20089892393018319715
   PubMed Web of Science ®Google Scholar
• KobayashiSBoggonTJDayaramTEGFR mutation and resistance of non-small-cell lung cancer to gefitinibN Engl J Med200535278679215728811
   PubMed Web of Science ®Google Scholar
• KosakaTYatabeYEndohHAnalysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinibClin Cancer Res2006125764576917020982
   PubMed Web of Science ®Google Scholar
• BeanJBrennanCShihJYMET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibProc Natl Acad Sci U S A2007104209322093718093943
   PubMed Web of Science ®Google Scholar